Molecular classification of breast cancer patients using formalin-fixed paraffin-embedded derived RNA samples
| Autor: | Brendan Yee, Christian Saliba, Godfrey Grech, Shawn Baldacchino, Keith Sacco, Christian Scerri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Receptor Status Pathology medicine.medical_specialty Biochemical markers RNA Biology medicine.disease Breast -- Cancer -- Patients 03 medical and health sciences Basal (phylogenetics) 030104 developmental biology Breast cancer Gene expression medicine Immunohistochemistry Multiplex Breast -- Cancer -- Molecular aspects Triple-negative breast cancer |
| Popis: | The use of archival formalin-fixed paraffin-embedded (FFPE) material to analyse gene expression is limited by the low quality of extracted RNA. In this paper, we utilised an RNA based assay to quantify expression of luminal and basal markers, together with ERBB2 probes, in FFPE archival tissue from 2009 to 2010, all of which had clinical and therapeutic information of more than 5 years. Receptor status of the patients was characterised using the QuantiGene® Plex assay with 100% concordance to immunohistochemical (IHC) and fluorescence in situ hybridisation (FISH) results. A panel of molecular markers known to classify luminal and basal tumours were used and correlated with receptor status of the tumours. As expected, the triple negative breast cancer (TNBC) samples were classified as basal and oestrogen receptor (ER) positive cases as luminal. In summary, the QuantiGene® Plex technology provides a platform to quantitate novel panels of biomarkers on archival material. Moreover, multiplex analysis allows the use of minimal amounts of material providing an opportunity to utilise laser micro-dissected material. FFPE tissue samples are an invaluable resource for retrospective studies to interrogate current novel biomarkers, particularly to generate disease free survival and overall survival graphs to measure predictive value using well annotated retrospective samples with full clinical and pharmacological outcomes. This study was funded by the Faculty of Medicine and Surgery, University of Malta and the Italia Malta Genome Breast Cancer Cross Border Risk Surveillance (ImaGenX) project financed under Operational Program Italia Malta 2007-2013 and co-financed by the University of Malta. peer-reviewed |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|